Compare ICFI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | PRCT |
|---|---|---|
| Founded | 1969 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2006 | 2021 |
| Metric | ICFI | PRCT |
|---|---|---|
| Price | $65.79 | $25.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $99.25 | $35.44 |
| AVG Volume (30 Days) | 259.3K | ★ 2.0M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 4.95 | N/A |
| Revenue | ★ $1,229,162,000.00 | $308,054,000.00 |
| Revenue This Year | $4.12 | $31.62 |
| Revenue Next Year | $5.33 | $24.45 |
| P/E Ratio | $13.42 | ★ N/A |
| Revenue Growth | 3.72 | ★ 37.22 |
| 52 Week Low | $65.00 | $19.35 |
| 52 Week High | $101.71 | $64.89 |
| Indicator | ICFI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 42.36 |
| Support Level | N/A | $19.35 |
| Resistance Level | $89.69 | $29.06 |
| Average True Range (ATR) | 2.73 | 1.51 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 1.52 | 20.24 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.